GLX351322
Catalog No.: GC31367Purity:>99.50%
GLX351322 ist ein Inhibitor der NADPH-Oxidase 4 (Nox4) und hemmt die Wasserstoffperoxidproduktion von NOX4-Überexprimierenden Zellen mit einem IC50 von 5 μM.
Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.
Cas No.: 835598-94-2
10mM (in 1mL DMSO)In Stock
$100.00
1
1mgIn Stock
$48.00
1
5mgIn Stock
$105.00
1
10mgIn Stock
$147.00
1
25mgIn Stock
$279.00
1
50mgIn Stock
$391.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $100.00 | In Stock | 1 | |
| 1mg | $48.00 | In Stock | 1 | |
| 5mg | $105.00 | In Stock | 1 | |
| 10mg | $147.00 | In Stock | 1 | |
| 25mg | $279.00 | In Stock | 1 | |
| 50mg | $391.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Zitate (Citations)
3 publicationsPublikationen von Forschern, die dieses Produkt verwendenBeschreibung (Description)
GLX351322 is a NADPH Oxidase 4 (NOX4) inhibitor, with an IC50 value of 5μM [1]. GLX351322 inhibits ROS/MAPK/NF-κB signaling pathways, exhibiting anti-inflammatory effect[2]. GLX351322 has been widely used in various animal models to regulate neural functions and reduce oxidative stress[3].
In vitro, GLX351322 (10μM) treatment for 3 hours reduced the production of reactive oxygen species (ROS) and cell death in human islet cells induced by high glucose and palmitate[4]. Treatment with 40μM GLX351322 for 24 hours inhibited the proliferation of hypoxia-induced leiomyoma cells and promoted cell apoptosis[5]. Treatment with 5μM GLX351322 for 48 hours enhanced the cell death of BCPAP and TPC-1 cells treated with Lenvatinib[6].
In vivo, GLX351322 treatment via oral administration at a dose of 3.8mg/kg/day for 2 weeks suppressed tumor growth and progression in Gl261 glioma cell-intracranial xenograft mice [7]. Continuous intraperitoneal injection of 5mg/kg/day dose of GLX351322 for four consecutive weeks rescued synaptic and memory deficits, and decreased oxidative stress and amyloid levels in the hippocampus of APP/PS1 mice [8].
References:
[1] Anvari E, Wikström P, Walum E, et al. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice[J]. Free radical research, 2015, 49(11): 1308-1318.
[2] Zhen J, Chen X, Mao Y, et al. GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF‐κB Signaling Pathways[J]. Oxidative Medicine and Cellular Longevity, 2023, 2023(1): 1952348.
[3] Kaur S, Verma R, Sharma V, et al. Targeting NOX inhibitors in neurodegeneration: a therapeutic perspective[J]. Metabolic Brain Disease, 2025, 40(5): 219.
[4] Wang X, Elksnis A, Wikström P, et al. The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro[J]. PLoS One, 2018, 13(9): e0204271.
[5] Miyashita-Ishiwata M, El Sabeh M, Reschke L D, et al. Hypoxia induces proliferation via NOX4-Mediated oxidative stress and TGF-β3 signaling in uterine leiomyoma cells[J]. Free radical research, 2022, 56(2): 163-172.
[6] Tang P, Sheng J, Peng X, et al. Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib[J]. Cell Death Discovery, 2022, 8(1): 177.
[7] Jiang H, Li F, Cai L, et al. Role of the TSPO–NOX4 axis in angiogenesis in glioblastoma[J]. Frontiers in Pharmacology, 2022, 13: 1001588.
[8] Tao W, Yu L, Shu S, et al. miR-204-3p/Nox4 mediates memory deficits in a mouse model of Alzheimer’s disease[J]. Molecular Therapy, 2021, 29(1): 396-408.
Protokoll (Protocol)
| Cell experiment [1]: | |
Cell lines | Primary human leiomyoma cells |
Preparation Method | Primary leiomyoma cells were preincubated without serum for 24h. The cells were then incubated in 2% or 21% O2 at 37 C with 10% FBS. After 24h, the media were removed, and the volume of the media was noted. Cells were seeded at a concentration of 0.6×105 cells/ml until 60-70% confluence, and were treated with GLX351322 (40μM) and incubated for 48h. Using 96-well plates, 3000 cells were seeded per well with a complete DMEM/F-12 media. One day after seeding, 20μl of 12μM MTT solution was added to each well, and cells were incubated for 3h. The media was removed, and 100ul/well DMSO was added. The absorbance at 570nm was monitored. |
Reaction Conditions | 40μM; 48h |
Applications | GLX351322 treatment significantly inhibited cell viability of leiomyoma cells exposed to hypoxia. |
| Animal experiment [2]: | |
Animal models | C57Bl/6J mice |
Preparation Method | Six-week-old C57Bl/6J mice were raised in a standard sterile environment. The mouse xenograft models were established by intracranial injection of Gl261 glioma cells (1×106cells/100μl). After the tumors grew for three weeks, all intracranial xenograft mice were divided into two groups: treatment group, which received normal saline (containing 3.8mg/kg of GLX351322) as drinking water daily for two consecutive weeks; control group, which did not receive GLX351322. Each group contained 7 C57Bl/6J mice. The brain tissues of the mice were collected for analysis. |
Dosage form | 3.8mg/kg/day for 2 weeks; p.o. |
Applications | GLX351322 treatment suppressed glioma growth and progression in mice and inhibited angiogenesis. |
References: | |
Produktdokumente (Product Documents)
Purity:>99.50%Appearance:A solid
Chemische Eigenschaften (Chemical Properties)
CAS-Nr.
835598-94-2
SMILES
O=C(OCC)C1=C(SC2=C1CCC2)NC(CN3CCN(CC3)C(C4=CC=CO4)=O)=O
Summenformel
C21H25N3O5S
Molekulargewicht
431.51
Löslichkeit
DMSO : 20 mg/mL (46.35 mM)
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.
Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit
g/mol
Reviews
Review for GLX351322
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%